Details of the Drug

General Information of Drug (ID: DM79NTF)

Drug Name
Propranolol
Synonyms
Anaprilin; Anapriline; Avlocardyl; Bedranol; Berkolol; Betachron; Betadren; Betalong; Caridolol; Corpendol; Dociton; Efektolol; Etalong; Euprovasin; Herzbase; Ikopal; Inderal; Inderalici; Inderex; Inderol; Intermigran; Kemi; Migrastat; Naprilin; Obsidan; Obzidan; Pranolol; Pronovan; Propanalol; Propanix; Propanolol; Propranalol; Propranololo; Propranololum; Proprasylyt; Reducor; Sawatal; Servanolol; Sumial; Beta Neg; Inderal hydrochloride; Kemi S; Propranolol Hcl Intensol; Propranololo [DCIT]; Racemic propranolol; Reducorline; AY 64043; AY-20694; Anaprilinum (TN); Avlocardyl (TN); Beta-Propranolol; Beta-Tablinen; Beta-Timelets; DL-Propranolol hydrochloride; Deralin (TN); Dociton (TN); Inderal (TN); Inderal LA (TN); Inderalici (TN); InnoPran XL (TN); Propanolol [INN-Spanish]; Propranolol (INN); Propranolol (TN); Propranolol [INN:BAN]; Propranololum [INN-Latin]; Sumial (TN); D,L-Propranolol; INDERIDE-40/25; R,S-Propranolol Hydrochloride; (+-)-Propranolol; (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; (R)-(+)-propranolol; (S)-(-)-PROPRANOLOL; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; 1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-(9CI); 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-(9CI); 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1], [2]
Therapeutic Class
Antianxiety Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 259.339
Topological Polar Surface Area (xlogp) 3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 18 +/- 15 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The clearance of drug is 2.7 +/- 0.03 L/h/kg [5]
Elimination
91% of an oral dose of propranolol is recovered as 12 metabolites in the urine [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 8 hours [7]
Metabolism
The drug is metabolized via side chain oxidation to -naphthoxylactic acid [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 35.2529 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.13% [10]
Vd
The volume of distribution (Vd) of drug is 4 L/kg or 320 L [3]
Water Solubility
The ability of drug to dissolve in water is measured as 50 mg/mL [4]
Chemical Identifiers
Formula
C16H21NO2
IUPAC Name
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
Canonical SMILES
CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
InChI
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3
InChIKey
AQHHHDLHHXJYJD-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4946
ChEBI ID
CHEBI:8499
CAS Number
525-66-6
DrugBank ID
DB00571
TTD ID
D04JEE
VARIDT ID
DR00528
INTEDE ID
DR1367
ACDINA ID
D00565

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [11]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 3 (SLC22A3) DT6201N S22A3_HUMAN Substrate [12]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [12]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [14]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [15]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [16]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [17]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [18]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [18]
Dimethylaniline oxidase 2 (FMO2) DEIASEZ FMO2_HUMAN Substrate [19]
Cytochrome P450 102A1 (cyp102) DE4OGUF CPXB_BACMB Substrate [20]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Propranolol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Rizatriptan DMDJMA3 Moderate Decreased metabolism of Propranolol caused by Rizatriptan mediated inhibition of non-CYP450 enzyme. Migraine [8A80] [110]
Coadministration of a Drug Treating the Disease Different from Propranolol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Propranolol caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [111]
Scopolamine DMOM8AL Moderate Antagonize the effect of Propranolol when combined with Scopolamine. Addictive disorder [6C50-6C5Z] [112]
Bepridil DM0RKS4 Moderate Increased risk of cardiac depression by the combination of Propranolol and Bepridil. Angina pectoris [BA40] [113]
Nifedipine DMSVOZT Moderate Increased risk of cardiac depression by the combination of Propranolol and Nifedipine. Angina pectoris [BA40] [113]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Propranolol caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [114]
Oxazepam DMXNZM4 Minor Decreased metabolism of Propranolol caused by Oxazepam. Anxiety disorder [6B00-6B0Z] [115]
Voriconazole DMAOL2S Moderate Decreased metabolism of Propranolol caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [112]
Zileuton DMVRIC2 Moderate Decreased metabolism of Propranolol caused by Zileuton. Asthma [CA23] [116]
Obeticholic acid DM3Q1SM Moderate Decreased metabolism of Propranolol caused by Obeticholic acid mediated inhibition of CYP450 enzyme. Autoimmune liver disease [DB96] [117]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Propranolol and Cariprazine. Bipolar disorder [6A60] [118]
Atracurium DM42HXN Moderate Additive cardiorespiratory depression effects by the combination of Propranolol and Atracurium. Corneal disease [9A76-9A78] [119]
Mivacurium DM473VD Moderate Additive cardiorespiratory depression effects by the combination of Propranolol and Mivacurium. Corneal disease [9A76-9A78] [119]
Pancuronium DMB0VY8 Moderate Additive cardiorespiratory depression effects by the combination of Propranolol and Pancuronium. Corneal disease [9A76-9A78] [119]
Tubocurarine DMBZIVP Moderate Additive neuromuscular blocking effects by the combination of Propranolol and Tubocurarine. Corneal disease [9A76-9A78] [119]
Pasireotide DMHM7JS Moderate Increased risk of bradycardia by the combination of Propranolol and Pasireotide. Cushing syndrome [5A70] [120]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Propranolol caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [121]
MK-8228 DMOB58Q Moderate Increased metabolism of Propranolol caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [122]
Sertraline DM0FB1J Moderate Decreased metabolism of Propranolol caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [123]
Paroxetine DM5PVQE Moderate Decreased metabolism of Propranolol caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [123]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Propranolol and OPC-34712. Depression [6A70-6A7Z] [118]
Maprotiline DMPWB7T Minor Decreased metabolism of Propranolol caused by Maprotiline. Depression [6A70-6A7Z] [124]
Mepenzolate DM8YU2F Moderate Antagonize the effect of Propranolol when combined with Mepenzolate. Digestive system disease [DE2Z] [112]
Oxybutynine DMJPBAX Moderate Antagonize the effect of Propranolol when combined with Oxybutynine. Discovery agent [N.A.] [111]
Diazepam DM08E9O Minor Decreased metabolism of Propranolol caused by Diazepam. Epilepsy/seizure [8A61-8A6Z] [115]
Primidone DM0WX6I Moderate Increased metabolism of Propranolol caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Oxcarbazepine DM5PU6O Moderate Decreased metabolism of Propranolol caused by Oxcarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [112]
Cenobamate DMGOVHA Moderate Decreased metabolism of Propranolol caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [126]
Stiripentol DMMSDOY Moderate Decreased metabolism of Propranolol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [127]
Brivaracetam DMSEPK8 Minor Decreased metabolism of Propranolol caused by Brivaracetam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [111]
Phenobarbital DMXZOCG Moderate Increased metabolism of Propranolol caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [125]
Ethacrynic acid DM60QMR Moderate Increased risk of hypertriglyceridemia by the combination of Propranolol and Ethacrynic acid. Essential hypertension [BA00] [128]
Phenoxybenzamine DM8KSQH Moderate Additive hypotensive effects by the combination of Propranolol and Phenoxybenzamine. Essential hypertension [BA00] [129]
Nicardipine DMCDYW7 Moderate Increased risk of cardiac depression by the combination of Propranolol and Nicardipine. Essential hypertension [BA00] [113]
Mirabegron DMS1GYT Moderate Decreased metabolism of Propranolol caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [130]
Tolterodine DMSHPW8 Moderate Antagonize the effect of Propranolol when combined with Tolterodine. Functional bladder disorder [GC50] [112]
Terbinafine DMI6HUW Moderate Decreased metabolism of Propranolol caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [131]
Propantheline DM2EN6G Moderate Antagonize the effect of Propranolol when combined with Propantheline. Gastric ulcer [DA60] [112]
Chlorothiazide DMLHESP Moderate Increased risk of hyperglycemia by the combination of Propranolol and Chlorothiazide. Heart failure [BD10-BD1Z] [128]
Furosemide DMMQ8ZG Moderate Increased risk of hyperglycemia by the combination of Propranolol and Furosemide. Heart failure [BD10-BD1Z] [128]
Bumetanide DMRV7H0 Moderate Increased risk of hyperglycemia by the combination of Propranolol and Bumetanide. Heart failure [BD10-BD1Z] [128]
Hydroflumethiazide DMVPUQI Moderate Increased risk of ventricular arrhythmias by the combination of Propranolol and Hydroflumethiazide. Heart failure [BD10-BD1Z] [128]
Rifampin DMA8J1G Moderate Increased metabolism of Propranolol caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [132]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Propranolol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [133]
Etravirine DMGV8QU Moderate Decreased metabolism of Propranolol caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [134]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Propranolol caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [112]
Teriflunomide DMQ2FKJ Moderate Increased metabolism of Propranolol caused by Teriflunomide mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [112]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Propranolol caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [112]
Levamlodipine DM92S6N Moderate Increased risk of cardiac depression by the combination of Propranolol and Levamlodipine. Hypertension [BA00-BA04] [113]
Doxazosin DM9PLRH Moderate Additive hypotensive effects by the combination of Propranolol and Doxazosin. Hypertension [BA00-BA04] [129]
Verapamil DMA7PEW Major Increased risk of cardiac depression by the combination of Propranolol and Verapamil. Hypertension [BA00-BA04] [113]
Indapamide DMGN1PW Moderate Increased risk of hypertriglyceridemia by the combination of Propranolol and Indapamide. Hypertension [BA00-BA04] [128]
Trichlormethiazide DMHAQCO Moderate Increased risk of ventricular arrhythmias by the combination of Propranolol and Trichlormethiazide. Hypertension [BA00-BA04] [128]
Felodipine DMOSW35 Moderate Increased risk of cardiac depression by the combination of Propranolol and Felodipine. Hypertension [BA00-BA04] [113]
Hydralazine DMU8JGH Minor Decreased metabolism of Propranolol caused by Hydralazine mediated interference with first-pass metabolism. Hypertension [BA00-BA04] [135]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of hyperglycemia by the combination of Propranolol and Hydrochlorothiazide. Hypertension [BA00-BA04] [128]
Clevidipine butyrate DMW4M97 Moderate Increased risk of cardiac depression by the combination of Propranolol and Clevidipine butyrate. Hypertension [BA00-BA04] [113]
Givosiran DM5PFIJ Moderate Decreased metabolism of Propranolol caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [136]
Belladonna DM2RBWK Moderate Antagonize the effect of Propranolol when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [111]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Propranolol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [137]
Amobarbital DM0GQ8N Moderate Increased metabolism of Propranolol caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [125]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Propranolol and Propiomazine. Insomnia [7A00-7A0Z] [118]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Propranolol and ITI-007. Insomnia [7A00-7A0Z] [118]
Clidinium DMUMQZ0 Moderate Antagonize the effect of Propranolol when combined with Clidinium. Irritable bowel syndrome [DD91] [111]
Dicyclomine DMZSDGX Moderate Antagonize the effect of Propranolol when combined with Dicyclomine. Irritable bowel syndrome [DD91] [111]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Propranolol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [111]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Propranolol caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [138]
Osimertinib DMRJLAT Moderate Increased metabolism of Propranolol caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [139]
Capmatinib DMYCXKL Moderate Decreased metabolism of Propranolol caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [140]
Lumefantrine DM29GAD Moderate Decreased metabolism of Propranolol caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [112]
Chloroquine DMSI5CB Minor Decreased metabolism of Propranolol caused by Chloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [141]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Propranolol caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [142]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Propranolol caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [111]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Propranolol caused by Ethinyl estradiol mediated interference with first-pass metabolism. Menopausal disorder [GA30] [143]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Propranolol due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [120]
Panobinostat DM58WKG Moderate Decreased metabolism of Propranolol caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [144]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Propranolol and Thalidomide. Multiple myeloma [2A83] [112]
Siponimod DM2R86O Major Increased risk of atrioventricular block by the combination of Propranolol and Siponimod. Multiple sclerosis [8A40] [112]
Fingolimod DM5JVAN Major Increased risk of bradycardia by the combination of Propranolol and Fingolimod. Multiple sclerosis [8A40] [145]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Propranolol and Ozanimod. Multiple sclerosis [8A40] [146]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Propranolol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [111]
Nilotinib DM7HXWT Moderate Decreased metabolism of Propranolol caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [147]
Imatinib DM7RJXL Moderate Decreased metabolism of Propranolol caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [148]
Modafinil DMYILBE Moderate Decreased metabolism of Propranolol caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [112]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Propranolol and Promethazine. Nausea/vomiting [MD90] [118]
Rolapitant DM8XP26 Moderate Decreased metabolism of Propranolol caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [149]
Bupropion DM5PCS7 Moderate Decreased metabolism of Propranolol caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [150]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Propranolol caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [151]
Polythiazide DMCH80F Moderate Increased risk of hyperglycemia by the combination of Propranolol and Polythiazide. Oedema [MG29] [128]
Olaparib DM8QB1D Moderate Increased metabolism of Propranolol caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [112]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Propranolol caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [152]
Dextropropoxyphene DM23HCX Moderate Decreased metabolism of Propranolol caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [153]
Biperiden DME78OA Moderate Antagonize the effect of Propranolol when combined with Biperiden. Parkinsonism [8A00] [112]
Abametapir DM2RX0I Moderate Decreased metabolism of Propranolol caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [154]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of Propranolol when combined with Methylscopolamine. Peptic ulcer [DA61] [111]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Propranolol caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [155]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Propranolol caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [156]
Enzalutamide DMGL19D Moderate Increased metabolism of Propranolol caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [157]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Propranolol and Terazosin. Prostate hyperplasia [GA90] [129]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Propranolol and Silodosin. Prostate hyperplasia [GA90] [129]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Propranolol and Levomepromazine. Psychotic disorder [6A20-6A25] [118]
Fluphenazine DMIT8LX Moderate Additive hypotensive effects by the combination of Propranolol and Fluphenazine. Psychotic disorder [6A20-6A25] [118]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Propranolol and Quetiapine. Schizophrenia [6A20] [118]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Propranolol and Mesoridazine. Schizophrenia [6A20] [118]
Thioridazine DM35M8J Major Decreased metabolism of Propranolol caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [158]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Propranolol and Aripiprazole. Schizophrenia [6A20] [118]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Propranolol and Iloperidone. Schizophrenia [6A20] [118]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Propranolol and Paliperidone. Schizophrenia [6A20] [118]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Propranolol and Perphenazine. Schizophrenia [6A20] [118]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Propranolol and Molindone. Schizophrenia [6A20] [118]
Thiothixene DMDINC4 Minor Increased plasma concentrations of Propranolol and Thiothixene due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [159]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Propranolol and Trifluoperazine. Schizophrenia [6A20] [118]
Risperidone DMN6DXL Moderate Additive hypotensive effects by the combination of Propranolol and Risperidone. Schizophrenia [6A20] [118]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Propranolol and Amisulpride. Schizophrenia [6A20] [111]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Propranolol and Asenapine. Schizophrenia [6A20] [118]
Armodafinil DMGB035 Moderate Decreased metabolism of Propranolol caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [112]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Propranolol and Pipecuronium. Tonus and reflex abnormality [MB47] [119]
Doxacurium DMKE7L9 Moderate Additive neuromuscular blocking effects by the combination of Propranolol and Doxacurium. Tonus and reflex abnormality [MB47] [119]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Propranolol and Vecuronium. Tonus and reflex abnormality [MB47] [119]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Propranolol and Rocuronium. Tonus and reflex abnormality [MB47] [119]
Atropine DMEN6X7 Moderate Antagonize the effect of Propranolol when combined with Atropine. Unspecific substance harmful effect [NE6Z] [111]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Propranolol and Methdilazine. Vasomotor/allergic rhinitis [CA08] [118]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Propranolol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [160]
Propafenone DMPIBJK Moderate Decreased metabolism of Propranolol caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [161]
Amiodarone DMUTEX3 Moderate Increased risk of atrioventricular block by the combination of Propranolol and Amiodarone. Ventricular tachyarrhythmia [BC71] [162]
⏷ Show the Full List of 124 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 30 E00456 3000709 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Dibutyl sebacate E00160 7986 Plasticizing agent
Diglycol stearate E00154 7788 Emulsifying agent; Opacifying agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 30 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Propranolol 10 mg tablet 10 mg Oral Tablet Oral
Propranolol 20 mg tablet 20 mg Oral Tablet Oral
Propranolol 40 mg tablet 40 mg Oral Tablet Oral
Propranolol 80 mg tablet 80 mg Oral Tablet Oral
Propranolol 60 mg tablet 60 mg Oral Tablet Oral
Propranolol 160 mg capsule 160 mg 24 HR Extended Release Oral Capsule Oral
Propranolol 120 mg capsule 120 mg 24 HR Extended Release Oral Capsule Oral
Propranolol 80 mg capsule 80 mg 24 HR Extended Release Oral Capsule Oral
Propranolol 60 mg capsule 60 mg 24 HR Extended Release Oral Capsule Oral
Propranolol 120 mg capsule 120 mg 24 HR Extended Release Capsule Oral
Propranolol 160 mg capsule 160 mg 24 HR Extended Release Capsule Oral
Propranolol 60 mg capsule 60 mg 24 HR Extended Release Capsule Oral
Propranolol 80 mg capsule 80 mg 24 HR Extended Release Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7596).
2 Emerging drugs for complications of end-stage liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):159-74.
3 Chidsey CA, Morselli P, Bianchetti G, Morganti A, Leonetti G, Zanchetti A: Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation. 1975 Aug;52(2):313-8. doi: 10.1161/01.cir.52.2.313.
4 BDDCS applied to over 900 drugs
5 FDA Approved Drug Products: HEMANGEOL (propranolol hydrochloride) oral solution
6 Walle T, Walle UK, Olanoff LS: Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos. 1985 Mar-Apr;13(2):204-9.
7 FDA Approved Drug Products: INNOPRAN XL (propranolol hydrochloride) extended release capsules
8 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
11 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
12 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
13 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
14 Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos. 1994 Nov-Dec;22(6):909-15.
15 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
16 Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001 Oct;52(4):349-55.
17 Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
18 The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
19 Human FMO2-based microbial whole-cell catalysts for drug metabolite synthesis. Microb Cell Fact. 2015 Jun 12;14:82.
20 acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
21 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
22 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
23 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
24 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
25 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
26 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
27 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
28 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
29 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
30 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
31 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
32 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
33 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
34 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
35 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
36 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
37 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
38 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
39 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
40 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
41 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
42 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
43 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
44 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
45 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
46 Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
47 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
48 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
49 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
50 Drug Interactions Flockhart Table
51 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
52 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
53 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
54 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
55 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
56 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
57 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
58 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
59 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
60 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
61 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
62 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
63 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
64 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
65 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
66 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
67 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
68 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
69 Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
70 The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
71 Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
72 Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
73 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
74 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
75 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
76 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
77 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
78 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
79 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
80 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
81 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
82 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
83 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
84 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
85 The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
86 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
87 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
88 Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
89 Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40.
90 Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
91 Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9.
92 Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31.
93 Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51.
94 Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
95 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
96 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
97 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
98 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
99 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
100 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
101 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
102 Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
103 Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
104 Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
105 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
106 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
107 beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
108 beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
109 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
110 Goldberg MR, Sciberras D, De Smet M, et al. "Influence of B-adrenoceptor antagonists on the ppharmacokinetics of rizatriptan, a 5-HT IB/ID agonist: differential effects of propranolol, nadolol and metoprolol." Br J Clin Pharmacol 52 (2001): 69-76. [PMID: 11453892]
111 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
112 Cerner Multum, Inc. "Australian Product Information.".
113 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
114 Haglund K, Seideman P, Colliste P, Borg KO, von Bahr C "Influence of pentobarbital on metoprolol plasma levels." Clin Pharmacol Ther 26 (1979): 326-9. [PMID: 466926]
115 Hawksworth G, Betts T, Crowe A, et al "Diazepam/beta-adrenoceptor antagonist interactions." Br J Clin Pharmacol 17 Suppl 1 (1984): s69-76. [PMID: 6146341]
116 Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
117 Product Information. Ocaliva (obeticholic acid). Intercept Pharmaceuticals, Inc., New York, NY.
118 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
119 Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
120 Canadian Pharmacists Association.
121 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
122 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
123 Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
124 Saiz-Ruiz J, Moral L "Delirium induced by association of propranolol." J Clin Psychopharmacol 8 (1988): 77-8. [PMID: 3351011]
125 Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
126 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
127 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
128 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
129 Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
130 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
131 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
132 Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE "Interaction of bisoprolol with cimetidine and rifampicin." Eur J Clin Pharmacol 31 (1986): 59-62. [PMID: 2877885]
133 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
134 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
135 Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21. [PMID: 1451723]
136 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
137 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
138 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
139 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
140 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
141 Lancaster DL, Adio RA, Tai KK, Simooya OO, Broadhead GD, Tucker GT, Lennard MS "Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs." J Pharm Pharmacol 42 (1990): 267-71. [PMID: 1974295]
142 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
143 Product Information. Betapace (sotalol). Berlex, Richmond, CA.
144 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
145 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
146 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
147 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
148 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
149 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
150 Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
151 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
152 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
153 Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40. [PMID: 1349528]
154 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
155 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
156 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
157 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
158 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
159 Ereshefsky L, Saklad SR, Watanabe MD, Davis CM, Jann MW "Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables." J Clin Psychopharmacol 11 (1991): 296-301. [PMID: 1765572]
160 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
161 Ahmad S "Metoprolol-induced delirium perpetuated by propafenone." Am Fam Physician 44 (1991): 1142,4. [PMID: 1927831]
162 Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]